Valuentum Exclusive Analysis for the Discerning Investor

Symbol Keyword

Apr 19, 2024

Dividend Increases/Decreases for the Week of April 19
Let's take a look at firms raising/lowering their dividends this week.

Apr 12, 2024

JPMorgan Cautious on Geopolitical Tensions and Inflationary Pressures
Image Source: Hakan Dahlstrom. On April 12, JPMorgan reported mixed first-quarter 2024 results. JPMorgan is one of our favorite banks, in part due to strong leadership at the top and solid fortress-like balance sheet. Though we don’t include any individual bank in the newsletter portfolios, we do think the Financial Select Sector SPDR makes sense for diversification reasons, as showcased in the Best Ideas Newsletter portfolio. Shares of JPMorgan yield ~2.4% at the time of this writing.

Mar 25, 2024

Fedex Bolstered By Cost Savings from Its DRIVE Program
Image: FedEx continues to extract cost savings from its DRIVE initiatives. FedEx is doing a lot of things right as it drives cost savings from its DRIVE program in the face of a challenging revenue environment. Shares of FedEx bounced nicely following the release of its fiscal third quarter report, and while they aren’t trading at bargain basement prices on the basis of our fair value estimate, we think shares could have upside to north of $300 based on the high end of our fair value estimate range. Shares yield ~1.8% at the time of this writing.

Mar 15, 2024

Dividend Increases/Decreases for the Week of March 15
Let's take a look at firms raising/lowering their dividends this week.

Mar 10, 2024

Abercrombie & Fitch’s Mighty Comeback!
Image Source: Abercrombie & Fitch. Abercrombie & Fitch is experiencing a resurgence as the company reconnects with its target market, and the traction it has regained with its customers is quite something. The firm noted that it continues to experience strong momentum across its brand portfolio, and its long-term target is to achieve $5 billion in global sales (its sales were $4.3 billion in its most recent fiscal year). For 2024, it expects net sales to expand 4%-6%, and for its operating margin to be ~12%, up 60 basis points from the mark it reached last year. Abercrombie swung to being significantly free cash flow positive in its most recently completed fiscal year, and it ended the period with a net cash position. The company’s comeback has been nothing short of remarkable. Fickle fashion trends make the stock difficult to consider for long-term investors, however.

Feb 18, 2024

Digital Realty Trust Has Bucked Broader REIT Sector Weakness
Image: Digital Realty Trust has outperformed the broader REIT sector by quite the margin since the beginning of 2023. Real estate investors have had a difficult time the past year, with shares of the Vanguard Real Estate Index ETF falling roughly 6% versus a 22%+ return on the S&P 500, both measured on a price-only basis. Data center REIT Digital Realty, however, has bucked the trend of the broader real estate sector’s weakness advancing 20% over the same time period on a price only basis. Digital Realty’s fourth-quarter results and guidance for 2024, released February 15, weren’t great, but the company is much better positioned than other REITs, in our view. Shares yield ~3.6% at the time of this writing.

Jan 26, 2024

Dividend Increases/Decreases for the Week of January 26
Let's take a look at firms raising/lowering their dividends this week.

Dec 11, 2023

Oracle’s “Business Is Good and Getting Better”
Image Source: Peter Kaminski. On December 11, Oracle reported mixed second-quarter results for its fiscal 2024 that showed total revenue advancing 5% on a year-over-year basis (4% in constant currency), slightly lower than expectations, and non-GAAP earnings per share of $1.34 that came in slightly ahead of what the market was looking for. The company’s non-GAAP operating margin of 43% in the quarter helped to drive non-GAAP net income 14% higher than the same period a year ago (11% in constant currency). We’re not letting the slight miss on the top line sway us from our constructive stance on shares. Our fair value estimate stands at $108 per share, about in-line with where shares are currently trading.

Dec 10, 2023

First Gene-Editing Therapy Coming to Market; Reiterating Our Positive Stance on Vertex Pharma
Credit: Darryl Leja, NHGRI. On December 8, 2023, the U.S. Food and Drug Administration announced that it had approved Vertex Pharma’s and CRISPR Therapeutics’ novel gene-editing therapy (“Casgevy” – exa-cel) for sickle cell disease [SCD] in patients that are 12 years of age or older. This is the first such approval of its kind in U.S. history and will likely open the door for more gene-editing therapies for other rare diseases in the future. Estimates indicate that roughly 16,000 people will be eligible for the treatment at an estimated cost of around $2.2 million each, according to Reuters. The one-time market size of roughly $35.2 billion is a needle-mover, but the pace and timing of adoption of the therapy among the eligible population is difficult to estimate at this time. Note also that the therapy is of one-time application, meaning the therapy is a functional cure and will not be a source of recurring revenue from each patient. Nevertheless, it is an exciting development for medical science.

Nov 3, 2023

People Love Their Starbucks
Image: Starbucks remains a strong free cash flow generator. Operational efficiencies, sales leverage and pricing strength helped drive Starbucks' GAAP operating income growth of 42.7% and non-GAAP earnings per share to $1.06 in the quarter, up 31% on a year-over-year basis. Starbucks ended its fourth quarter of fiscal 2023 with ~$3.95 billion in cash and short-term investments and short- and long-term debt of ~$15.4 billion, resulting in a net debt position on the books. Free cash flow generation remains robust at Starbucks, however, with the measure coming in at ~$3.7 billion for the fiscal year ending October 1, 2023. We’re reiterating the high end of our fair value estimate range of $120 for Starbucks’ shares.